FDA considers deregulating unproven peptides amid corporate lobbying and anti-regulatory narratives from anti-vaxx elites - systemic health governance analysis

Indigenous and traditional medical systems have long used peptide-rich substances within holistic frameworks that balance efficacy with cultural and spiritual safety protocols. For example, the use of deer antler velvet in Mongolian and Siberian shamanic practices is governed by seasonal harvesting, spiritual preparation, and dosage rituals that Western science has largely ignored. The FDA's potential deregulation of peptides disregards these systemic safeguards, reducing complex biological compounds to marketable commodities devoid of cultural context. This reflects a colonial pattern where indigenous knowledge is either dismissed or exploited without reciprocity.

Historically, deregulation of unproven substances has preceded major public health crises, from the 19th-century patent medicine era to the 2000s opioid epidemic, where 'miracle cures' were later revealed to cause addiction and death. The FDA's 1994 Dietary Supplement Health and Education Act (DSHEA) created a regulatory loophole for peptides by classifying them as supplements, leading to a proliferation of untested products. Anti-regulatory movements, including those led by figures like RFK Jr., have repeatedly framed oversight as 'tyranny,' ignoring how such deregulation enables corporate exploitation of vulnerable populations. This pattern mirrors the 1920s-era snake oil salesmen, where deregulation and misinformation created a public health free-for-all.

Cross-culturally, the FDA's approach reflects a Western biomedical paradigm that prioritizes individual biochemical intervention over systemic health governance. In contrast, many African and Indigenous systems emphasize communal health, where substances like peptides are used within broader dietary, spiritual, and environmental frameworks. The Maori concept of 'whakapapa' (genealogy) ties health to land and community, contrasting sharply with the FDA's potential deregulation, which isolates peptides from their ecological and cultural contexts. This reflects a broader tension between Western reductionism and holistic, systemic health models.

Scientifically, peptides are short chains of amino acids with potential therapeutic applications, but their unregulated use poses significant risks, including contamination, improper dosing, and interactions with medications. The FDA's current framework requires rigorous testing for safety and efficacy, but deregulation would shift this burden to consumers and healthcare providers, exacerbating health disparities. Peer-reviewed studies on peptide-based therapies are limited, and much of the 'evidence' cited by proponents comes from anecdotal reports or industry-funded research. The scientific consensus emphasizes caution, yet the narrative framing this debate as 'bureaucratic overreach' ignores this evidence.

Artistically and spiritually, the deregulation of peptides intersects with a broader cultural narrative that glorifies 'biohacking' and 'self-optimization' at the expense of communal well-being. Figures like RFK Jr. and the MAHA movement frame health as a personal responsibility, ignoring how systemic factors like poverty, pollution, and corporate malfeasance shape health outcomes. This individualistic framing mirrors the capitalist ethos that reduces health to a commodity, erasing the spiritual and artistic dimensions of healing that emphasize balance, harmony, and community. The potential deregulation of peptides thus reflects a deeper cultural crisis where health is commodified rather than nurtured.

Future modelling suggests that deregulating peptides could lead to a surge in untested 'wellness' products, particularly in the $50 billion supplement industry, with predictable public health consequences. Scenario planning indicates that without robust oversight, peptides could become the next opioid crisis, with vulnerable populations—such as athletes, bodybuilders, and chronically ill individuals—bearing the brunt of harms. The FDA's potential move also sets a precedent for further deregulation of other unproven substances, eroding public trust in regulatory agencies and exacerbating health inequities. Conversely, a precautionary approach could incentivize innovation in peptide-based therapies while protecting public health.

Marginalized voices, including public health scientists, epidemiologists, and communities affected by peptide-related harms, are entirely absent from this narrative. The framing centers elite anti-regulatory figures like RFK Jr., who have significant platforms but lack scientific credibility on these issues. Communities of color, who are disproportionately targeted by unproven 'wellness' products, are also excluded from the debate, despite bearing the brunt of deregulatory policies. Additionally, healthcare providers serving marginalized populations, who witness the real-world consequences of unregulated substances, are sidelined in favor of ideological rhetoric.